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Abstract
Background: Untreated, miliary tuberculosis (TB) has a mortality approaching 100%. As it is uncommon there is
little specific data to guide its management. We report detailed data from a UK cohort of patients with miliary
tuberculosis and the associations and predictive ability of admission blood tests with clinical outcomes.
Methods: Routinely collected demographic, clinical, blood, imaging, histopathological and microbiological data
were assessed for all patients with miliary TB identified from the London TB register from 2008 to 2012 from
Northwest London Hospitals NHS Trust. Multivariable logistic regression was used to assess factors independently
associated with the need for critical care intervention. Receiver operator characteristics (ROC) were calculated to
assess the discriminatory ability of admission blood tests to predict clinical outcomes.
Results: Fifty-two patients were identified with miliary tuberculosis, of whom 29% had confirmed central nervous
system (CNS) involvement. Magnetic resonance imaging (MRI) was more sensitive than computed tomography (CT)
or lumbar puncture for detecting CNS disease. Severe complications were frequent, with 15% requiring critical care
intervention with mechanical ventilation. This was independently associated with admission hyponatraemia and
elevated alanine aminotransferase (ALT). Having an admission sodium ≥125 mmol/L and an ALT <180 IU/L had
82% sensitivity and 100% specificity for predicting a favourable outcome with an area under the ROC curve (AUC)
of 0.91. Despite the frequency of severe complications, one-year mortality was low at 2%.
Conclusions: Although severe complications of miliary tuberculosis were frequent, mortality was low with timely
access to critical care intervention, anti-tuberculous therapy and possibly corticosteroid use. Clinical outcomes could
accurately be predicted using routinely collected biochemistry data.
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Background
Tuberculosis is one of the leading causes of death from
infectious diseases worldwide [1]. Miliary tuberculosis
results from widespread haematogenous spread of the
Mycobacterium tuberculosis bacilli (TB). Clinical presenta-
tions are protean and vary from vague constitutional upset
in ambulatory patients to abrupt multi-organ failure [2].
Untreated, miliary TB has a mortality approaching 100%
[3], reducing to 7.1-30% with treatment [2, 4–6].
Miliary TB is uncommon, comprising 1-2% of TB cases
[2], thus specific data regarding its management, particu-
larly the ability to identify patients at high risk of poor out-
comes, are lacking [2]. Current treatment guidelines are
largely extrapolated from randomised controlled trials of
pulmonary TB rather than specific trials of patients with
miliary TB. As such, insights provided by cohort studies are
important in guiding best practice. However, most cohorts
are small and from the developing world, with limited neu-
roimaging and microbiological data. We sought to charac-
terise the clinical course, investigation findings, and
outcomes of a cohort with miliary TB from an ethnically
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diverse population with one of the highest TB incidences in
the UK [7].
Methods
Participants
Patients with miliary TB were identified from the
London TB register (LTBR) from 2008 to 2012 at
Northwest London Hospitals NHS Trust. These records
were cross-checked against the hospital database of all
in-patient admissions.
Data collection
Diagnosis of miliary TB was confirmed by identification
of the characteristic miliary pattern on chest radiograph
or computed tomography (CT) along with one or more
of the following features: clinical features compatible
with TB and response to anti-tuberculous therapy
(ATT); histopathological evidence of TB; microbiological
evidence of TB (positive smear or culture). Demo-
graphic, clinical, biochemical, radiological, histopatho-
logical evidence of TB (caseating or non-caseating
granulomas with or without acid-alcohol fast bacilli on
Ziehl-Neelson staining), and microbiological data were
obtained from the LTBR and the hospital electronic pa-
tient records.
Statistical analysis and biomarker selection
Univariate analysis of continuous data was performed
using t-tests and the Mann-Whitney U tests as appropri-
ate. For subsequent biomarker analysis, the primary out-
come of interest, defined as an ‘unfavourable outcome’,
was the need for critical care intervention with mechan-
ical intervention. Whereas, a ‘favourable outcome’ was
defined as not requiring critical care intervention with
mechanical ventilation.
Multivariable logistic regression (p < 0.1 for entry from
univariable logistic regression) was used to assess factors
associated with the need for critical care intervention.
Biomarkers that were independently associated with the
need for critical care intervention (i.e. an ‘unfavourable
outcome’) in the multivariable model were then assessed
for their predictive performance by determining their re-
ceiver operator characteristics (ROC). Biomarker classifi-
cation thresholds were determined by optimising the
balance of sensitivity and specificity. Biomarker classifica-
tion performance was assessed and thresholds determined
using the area under the ROC curve (AUC). This is
equivalent to the balanced accuracy of the classifier (i.e.
accuracy taking account of differences in prevalence of the
outcome between groups) for both ‘favourable’ (i.e. not re-
quiring critical care intervention) and ‘unfavourable’ out-
comes. Additionally, sensitivity, specificity, positive and
negative predictive values were calculated. Confidence
intervals were determined using bootstrapping with 1000
replicates.
Biomarkers were combined using an exhaustive grid
across the range of all possible values and combinations
to determine the optimum threshold for each biomarker
in combination so that the AUC was maximised.
Biomarker validation
Given the relatively small size of the dataset, splitting the
data into separate training and testing datasets would be
subject to bias. Therefore, to validate the predictive rule in
this dataset, a leave-one-out-cross-validation (LOOCV)
scheme was used. This entailed leaving one subject out of
the dataset, then performing an exhaustive grid search, as
before, to determine the optimal thresholds for the bio-
marker(s) of interest. This threshold(s) was then applied to
the case that was left out. These steps were then repeated
and summary statistics across the range of folds were cal-
culated. Accuracy was determined by the percentage of
correct responses across all the cross-validation folds.
Results
Baseline characteristics
Table 1 summarises the demographic data, investigations
and clinical outcomes of the cohort of 52 patients with
miliary TB. Thirty-six (69%) had typical miliary changes
on chest radiographs with the remainder having miliary
appearances confirmed on chest CT. The majority of pa-
tients (90%) were not born in the UK, had no significant
comorbidity, and were nearly all (94%) vitamin D defi-
cient. Half (14/24) had tuberculin skin test anergy and
6% were HIV co-infected. All but one patient (98%) were
admitted to hospital with a median length of stay of
11 days (range 1 – 233 days).
Neuroimaging
Nineteen patients (37%) had a CT brain scan performed
on their initial admission. Of these, 6 (31%) had ring-
enhancing lesions typical of tuberculomas. Eleven pa-
tients (21%) underwent magnetic resonance imaging
(MRI) of their brain, of whom 10 (91%) demonstrated
tuberculomas. Notably, 4 patients with normal/nonspe-
cific admission CT had subsequent MRI because due to
clinical concern of neurological disease, all of whom
demonstrated tuberculomas. The overall prevalence of
tuberculomas seen on MRI or CT was 12 of 23 (52%),
but we may have missed lesions in the 29 patients who
did not undergo neuroimaging, and in patients in whom
tuberculomas developed subsequently.
Microbiology
Forty patients (77%) had positive cultures forM. tuberculosis
(MTB) complex. Induced sputa lead to a positive culture in
thirty (58%) patients. Only ten sputum samples (19%)
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revealed acid-alcohol fast bacilli (AFB) on microscopy.
Seventeen patients (33%) had cerebrospinal fluid (CSF)
examination. Of these, four (24%) had findings compatible
with TB meningitis, all of whom subsequently cultured
MTB (two of four [50%] had tuberculomas). Aside from
sputa and CSF, MTB was cultured from joint (n = 2), peri-
cardial (n = 2) and pleural (n = 1) fluids (n = 1), transbron-
chial biopsy (n = 1) and bone marrow (n = 1). Four (10%)
were resistant to isoniazid, three (6%) to pyrazinamide, three
(6%) to streptomycin, one to rifampicin and isoniazid (i.e.
multidrug resistant – MDR) and none to ethambutol.
Treatment
All patients were commenced on quadruple ATT with
most receiving rifampicin, isoniazid, pyrazinamide and
ethambutol. Median (range) duration of ATT was 12 (1.5
– 28) months. Ten (19%) patients stopped pyrazinamide
due to drug-induced liver injury (15%) or intolerance
(4%). 29 patients (56%) received corticosteroids during
their ATT for a variety of indications including central
nervous system (CNS) involvement, systemic inflamma-
tory response syndrome and paradoxical reactions.
Complications
Follow-up to one-year was complete for 49 patients (94%).
One 87-year-old patient with multiple co-morbidities, in-
cluding chronic renal failure, died during treatment (after
1.5 months’ therapy). One patient died subsequently from
constrictive pericarditis secondary to pericardial involve-
ment, two years after successfully completing 12 months
of ATT.
Eight patients (15%) required critical care intervention
with mechanical ventilation, seven with respiratory failure
and one with neurologic deterioration. Other serious
adverse events are shown in Table 1. Corticosteroid use
was more frequent (88% vs. 50%, p = 0.11) in patients that
required mechanical ventilation. In a univariate model, re-
quirement for mechanical ventilation was associated with
thrombocytopenia (median platelet count in those
Table 1 Baseline characteristics, co-morbidities, admission blood
tests, neurological tests and outcomes of a UK cohort of patients
with miliary tuberculosis
Variable n (%) or
median (range)
Age (years) 41 (10-87)
Sex
Male 31 (60%)
Ethnic Origin
Asian 32 (62%)
Black-African 11 (21%)
White 5 (10%)
Other 4 (8%)
Previous diagnosis of TB 2 (4%)
Co-morbidities
None 33 (63%)
Diabetes 6 (12%)
CKD 4 (8%)
Anti-TNF therapy 3 (6%)
Alcoholism 3 (6%)
Heart failure 2 (4%)
HIV positive 3/49 (6%)
Hepatitis B sAg positive 3/49 (6%)
Hepatitis C positive 1/47 (2%)
Vitamin D deficient 44/57 (94%)
Admission blood tests
Sodium (mmol/L) 132 (106-141)
Creatinine (mmol/L) 68 (44-559)
Alanine aminotransferase (IU/L) 46 (5-453)
Alkaline phosphatase (iU/L) 121 (39-866)
Bilirubin (μmol/L) 12 (4-39)
Erythrocyte sedimentation rate (mm/h) 33 (1-127)
C-reactive protein (mg/L) 56 (3-433)
White cell count (×109/L) 7.1 (1.1-17.0)
Neutrophil count (×109/L) 5.3 (0.9-15.7)
Platelet count (×109/L) 238 (53-574)
Ferritin (μg/L) 522 (10-19,070)
Vitamin D (nmol/L) 16 (2-117)
Assessment for CNS involvement
Number of patients assessed for CNS infection 29 (56%)
- CT head consistent with CNS infection 6/19 (32%)
- MRI brain consistent with CNS infection 10/11 (91%)
- Lumbar puncture consistent with CNS infection 4/17 (24%)
Total number with confirmed CNS infection 15 (29%)
Outcomes and adverse events
Death (by one-year) 1 (2%)
Mechanical ventilation 8 (15%)
Table 1 Baseline characteristics, co-morbidities, admission blood
tests, neurological tests and outcomes of a UK cohort of patients
with miliary tuberculosis (Continued)
Drug-induced hepatitis 7 (13%)
Seizure 4 (8%)
Pneumothorax 3 (6%)
Haemophagocytic lymphohistiocytosis 2 (4%)
Pericardial effusion 2 (4%)
Data are presented as n (%), except for age and blood tests results which are
presented as median (range)
Abbreviations: TB Tuberculosis, CKD chronic kidney disease, TNF tumour
necrosis factor, HIV human immunodeficiency virus, CNS central nervous
system, CT computer tomography; MRI: magnetic resonance imaging, sAG
surface antigen
Underwood et al. BMC Infectious Diseases  (2017) 17:295 Page 3 of 7
needing: 148 × 109/L vs. not needing mechanical ventila-
tion: 266 × 109/L, p = 0.04), hyponatraemia (125 vs.
133 mmol/L, p = 0.03), hyperbilirubinaemia (17 vs.
11 μmol/L, p < 0.01), and increased alanine aminotrans-
ferase (ALT: 196 vs. 35 IU/L, p < 0.001). There were bor-
derline associations with increased erythrocyte
sedimentation rate (37 vs. 18 mm/h, p = 0.08) and c-
reactive protein (97 vs 48 mg/L, p = 0.06) among those re-
quiring mechanical ventilation. There was no significant
association between requirement for mechanical ventila-
tion and age (p = 0.72), admission vitamin D (p = 0.39),
total white cell count (p = 0.14), neutrophil count
(p = 0.45), creatinine (p = 0.34), alkaline phosphatase
(p = 0.53) nor ferritin (p = 0.54 but data were only avail-
able for 23/52). Additionally, neither comorbidity nor eth-
nicity were associated with the need for critical care
intervention (p > 0.8 for all). Whilst there was a trend for
a difference in the distribution of ESR between those who
did and did not require critical care intervention, in a uni-
variable logistic regression model it was not predictive
(odds ratio [95% confidence intervals]: 0.98 [0.94-1.01] per
100 mm/h; p = 0.19). Therefore, ESR was not included in
the multivariable model. In a multivariable logistic regres-
sion model, only sodium (OR [95% CIs] 0.19 [0.02-0.93]
per 10 mmol/L reduction, p = 0.04) and an ALT (1.33
[1.11-1.78] per 10 IU/L increase, p < 0.0001) were
independently associated with the need for mechanical
ventilation (Table 2).
Admission ALT and sodium were both independently as-
sociated with the need for critical care intervention with
mechanical ventilation and therefore underwent further
ROC analysis to determine predictive thresholds. For the in-
dependent prediction of an unfavourable outcome, the opti-
mal threshold for admission ALT was ≥180 IU/L and for
admission sodium was <132 mmol/L (Fig. 1 and Table 3).
The addition of sodium to ALT did not alter classification
performance, suggesting that using ALT ≥180 IU/L is suffi-
cient to predict an unfavourable outcome with a posi-
tive likelihood ratio of 32.6. Conversely, for the prediction
of a favourable outcome, a different threshold for sodium
was evident and classification performance was improved
by combining ALT <180 IU/L (individual AUC: 0.864) and
sodium ≥125 mmol/L (individual AUC: 0.670) thresholds
(combined AUC 0.909, Table 3). It should be noted that this
is equivalent to using an ALT threshold ≥180 IU/L or so-
dium <125 mmol/L as criteria from predicting an unfavour-
able outcome. The relationship between admission sodium
and ALT with outcomes is displayed graphically in Fig. 1.
Given the size of the dataset, biomarker prediction
validity was assessed using LOOCV. For the prediction
of an unfavourable outcome the median (range) ALT
threshold was: ≥180 (180-191) IU/L with diagnostic ac-
curacy of 92.3% across the cross-validation folds. For the
prediction of a favourable outcome, the median (range)
ALT threshold was <191 (180-200) IU/L; and for sodium
was: ≥125 (106-126) mmol/L yielding a diagnostic accur-
acy of 76.9% across the cross-validation folds.
Discussion
We report the lowest one-year mortality from miliary
TB (2%), despite significant rates of severe complica-
tions. Additionally, we demonstrate how routinely col-
lected biochemical measures can be used to accurately
predict clinical outcomes.
The mortality rate in our cohort compares favourably to
previously reported rates of 10-30% from the developing
world and 7.1%-21% from the developed world [2, 4–6].
Critical care intervention and mechanical ventilation, which
was required in 15% of our cohort, are likely to be respon-
sible for the low mortality we report as these patients would
almost certainly have died if these facilities were not avail-
able. Additionally, extensive experience in the management
of complicated tuberculosis at a high-volume centre are
likely to have contributed to our low mortality. Due to the
retrospective nature of data collection it was not possible to
assess the impact of corticosteroid usage on outcome, and
whilst corticosteroid usage was higher in patients requiring
mechanical ventilation this may reflect increased rates of
CNS involvement and systemic inflammatory response
syndrome in patients requiring critical care support. The
impact of corticosteroids on mortality in CNS TB infection
has been demonstrated, particularly in non HIV-infected
individuals [8]. Furthermore, meta-analysis of cortico-
steroid use in all forms of TB suggest a beneficial ef-
fect on mortality, however many of the 41
randomised controlled trials were identified as being
Table 2 Univariable and multivariable logistic regression model results for the outcome of requiring critical care intervention
Parameter Univariable Multivariable
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
ALT (per 10 IU/L) 1.29 (1.13-1.56) <0.001 1.33 (1.11-1.78) <0.001
Bilirubin (per 10 μmol/L) 2.99 (1.29-7.84) 0.01 0.69 (0.07-3.86) 0.68
CRP (per 10 mg/L) 1.14 (1.02-1.35) 0.02 1.13 (0.93-1.61) 0.27
Platelet count (per 100 cells/mm3) 0.39 (0.14-0.87) 0.02 0.75 (0.13-3.60) 0.71
Sodium (per 10 mmol/L) 0.40 (0.14-1.03) 0.06 0.19 (0.02-0.93) 0.04
Abbreviations: ALT alanine aminotransferase, CI confidence intervals; CRP c-reactive protein
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at high risk of bias, and none were performed to as-
sess corticosteroid usage specifically in miliary TB [9].
Given the multisystem nature of miliary TB with fre-
quent and potentially under-recognised CNS involve-
ment, further research is warranted to clarify the role
of corticosteroids.
Hyponatraemia and an elevated ALT on admission were
associated with an unfavourable clinical course. The causes
of hyponatraemia in those with miliary TB are numerous,
but are likely to include brain injury as well as adrenal and
pituitary dysfunction. Whereas, an increased ALT identifies
those with significant liver injury and in this cohort a
a
c
b
Fig. 1 Predictive characteristics of admission sodium and alanine aminotransferase for adverse clinical outcomes. Top: Receiver operator
characteristics of admission sodium (a) and alanine aminotransferase (b) for predicting the need for critical care intervention with mechanical
intervention with displayed statistics. Bottom: c graphically depicts patients by need for critical care intervention with cut-offs for admission
sodium and alanine aminotransferase that identify a favourable outcome with 100% specificity. Abbreviations: ALT: alanine aminotransferase;
Na: sodium; Sens: sensitivity; Spec: specificity; LR+: positive likelihood ratio; LR-: negative likelihood ratio
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threshold of ≥180 IU/L was strongly predictive of an
unfavourable outcome. Both factors are likely surrogates of
disease burden, hence their association with clinical
outcomes. Our data suggests these routinely collected
biochemical measures could be used to identify patients
with severe disease at risk of deterioration. However, these
thresholds need verifying in an independent dataset. Pend-
ing further study, they should be interpreted with caution
given the relatively low number of patients in our study.
Furthermore, the influence of co-morbidity, in particular
HIV-infection and type 2 diabetes given their increasing
prevalence in regions with the highest burden of tubercu-
losis, on the relationship between predictive biomarkers
and outcomes needs to be determined.
UK National Institute for Health and Care Excellence
(NICE) guidelines [10] currently recommend neuroim-
aging only for miliary TB patients with CNS signs or
symptoms. Given that miliary TB is caused by the wide-
spread haematogenous dissemination of MTB, it is un-
surprising that CNS involvement was proven in 29% of
our cohort. However, as not all our patients underwent
systematic neuroimaging or CSF sampling, this repre-
sents the lower bound of the true prevalence of CNS
disease and confirms historical autopsy data document-
ing high rates of CNS disease [11]. In keeping with other
studies, MRI was more sensitive than CT in detecting
tuberculomas [4]. CSF examination demonstrated TB
meningitis in a minority, suggesting that meningitis may
be a late manifestation of disease, however, normal CSF
biochemistry and microscopy did not exclude CNS in-
volvement. In addition, CNS tubercles may initially be
below the size of detection by CT or MRI, and may
paradoxically appear during treatment.
There are no randomised trials to provide guidance on
duration of therapy for miliary TB. A 6-month course is
currently recommended for miliary TB without CNS in-
volvement in UK, USA, Europe and WHO international
guidelines [10, 12–14]. However, as we suspect CNS in-
volvement in miliary TB is often under-recognised, a 6-
month course of ATT may risk later relapse and compli-
cations. Generally, patients in our cohort were treated for
12-months. Whether this contributed to our low mortality
is unclear. Given the ubiquity of CNS involvement, we ad-
vocate performing contrast-enhanced neuroimaging
(ideally MRI) in all patients and CSF examination in those
with symptoms or signs of meningitis. Ideally, this should
be at the time of diagnosis and possibly repeated 6-
12 weeks later to detect tuberculomas which appear dur-
ing treatment [15]. In settings where this is not possible,
9-12 months’ treatment to cover CNS disease may be pru-
dent. Given the high a priori probability of CNS disease,
we advocate consideration for longer empirical duration
of therapy (9-12 months) if contrast-enhanced MRI and
CSF examination cannot be undertaken, such as in the de-
veloping world.
The limitations of this case series include the retro-
spective and non-systematic nature of initial data collec-
tion and incomplete post-treatment follow-up. However,
most mortality attributed to miliary TB occurs in the
early stages of disease so it is unlikely that longer follow-
up would significantly change our conclusions [16, 17].
Additionally, due to the low mortality in our co-
hort, where there was only one death, we lacked power
to detect associations with this important outcome.
Conclusions
CNS involvement in miliary TB is common and is likely to
be under-recognised and under-treated. Although severe
complications occur frequently, they can be predicted by
admission hyponatraemia and increased ALT. A low one-
year mortality is achievable in a high resource setting with
critical care support and mechanical ventilation. Further re-
search is required to establish the role of corticosteroids
and prolonged ATT in the management of miliary TB.
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